Glucokinase (GK) is a monomeric allosteric enzyme and plays a pivotal role in blood glucose homeostasis. GK is regulated by GK regulatory protein (GKRP), and indirectly by allosteric effectors of GKRP. Despite the critical roles of GK and GKRP, the molecular basis for the allosteric regulation mechanism of GK by GKRP remains unclear. We determined the crystal structure of Xenopus GK and GKRP complex in the presence of fructose-6-phosphate at 2.9 Å. GKRP binds to a super-open conformation of GK mainly through hydrophobic interaction, inhibiting the GK activity by locking a small domain of GK. We demonstrate the molecular mechanism for the modulation of GK activity by allosteric effectors of GKRP. Importantly, GKRP releases GK in a sigmoidal manner in response to glucose concentration by restricting a structural rearrangement of the GK small domain via a single ion pair. We find that GKRP acts as an allosteric switch for GK in blood glucose control by the liver.hexokinase | sigmoidicity I conformational restriction | type 2 diabetes

Interleukin-6 (IL-6) is a multifunctional cytokine that regulates immune responses for host defense and tumorigenic process. Upregulation of IL-6 is known to constitutively phosphorylate signal transducer and activator of transcription 3 (STAT3), leading to activation of multiple oncogene pathways and inflammatory cascade. Here, we present the development of a high-affinity protein binder, termed repebody, which effectively suppresses non-small cell lung cancer in vivo by blocking the IL-6/STAT3 signaling. We selected a repebody that prevents human IL-6 (hIL-6) from binding to its receptor by a competitive immunoassay, and modulated its binding affinity for hIL-6 up to a picomolar range by a modular approach that mimics the combinatorial assembly of diverse modules to form antigen-specific receptors in nature. The resulting repebody was highly specific for hIL-6, effectively inhibiting the STAT3 phosphorylation in a dose- and binding affinity-response manner in vitro. The repebody was shown to have a remarkable suppression effect on the growth of tumors and STAT3 phosphorylation in xenograft mice with non-small cell lung cancer by blocking the hIL-6/STAT3 signaling. Structural analysis of the repebody and IL-6 complex revealed that the repebody binds the site 2a of hIL-6, overlapping a number of epitope residues at site 2a with gp130, and consequently causes a steric hindrance to the formation of IL-6/IL-6Rα complex. Our results suggest that high-affinity repebody targeting the IL-6/STAT3 pathway can be developed as therapeutics for non-small cell lung cancer.

Supplementary data are available at Bioinformatics online.

Enzymes with a product inhibition are generally considered a limiting step of the metabolic pathway in producing valuable compounds. Most attempts to relieve the product inhibition have relied on mutations at the productbinding site of enzymes. However, such an approach has resulted in a severe decrease in the catalytic activity, mainly owing to the shared binding site of product with substrate. Herein, we present the modulation of the conformational dynamics of chorismate-pyruvate lyase (CPL) for relieving the product inhibition without a decrease in the catalytic efficiency. CPL is a key enzyme in the biosynthesis of diverse aromatics but incurs a severe product inhibition owing to a strong product binding. On the basis of a structural analysis and molecular dynamics simulations, two key residues were identified for increasing the conformational dynamics of the flaps and thereby facilitating the product release. The designed mutants exhibited almost an 8-fold reduction in product inhibition and a 3-fold higher catalytic rate in comparison to the wild type. We demonstrate that mutation at two key residues leads to a significant increase in the conformational dynamics of the flaps, enhancing the product release through an opening of the flaps and thereby relieving the product inhibition.

Quorum sensing is a cell-cell communication mechanism that is involved in the regulation of biological functions such as luminescence, virulence, and biofilm formation. Quorum-quenching enzymes, which interrupt quorum-sensing signaling through degradation of quorum-sensing molecules, have emerged as a new approach to controlling and preventing bacterial virulence and pathogenesis. In an effort to develop quorum-quenching enzymes with improved catalytic activities, a genetic circuit system based on acylhomoserine-lactone (AHL)-mediated quorum-sensing signaling was constructed. The genetic circuit system was composed of lux-R, lux-I promoter, beta-lactamase, and beta-lactamase inhibitor, and designed to confer antibiotic resistance on host cells expressing an AHL-degrading enzyme, thereby enabling rapid screening of quorum-quenching enzymes. To demonstrate the utility of the genetic circuit system, we attempted the directed evolution of the AHL hydrolase from Bacillus sp. The genetic circuit system was shown to be effective in screening of quorum-quenching enzymes with high catalytic efficiency. From these results it is expected that the genetic circuit system can be widely used for the isolation and directed evolution of quorum-quenching enzymes with greater potential.